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Abstract:  The prevalence of overweight and obesity and their associated metabolic 
disorders are considered a major threat to the public’s health. While several diet and 
exercise programs are available for weight loss and prevention of weight regain, progress 
is  often slow and disappointing. Recently, natural bioactive phytochemicals present in 
foods have been discovered for their potential health benefit effects on the prevention of 
chronic disorders such as cancer, cardiovascular disease, inflammatory and metabolic 
diseases including obesity. Polyphenols are a class of naturally-occurring phytochemicals, 
of which some such as catechins, anthocynines, resveratrol and curcumin have been shown 
to modulate physiological and molecular pathways that are involved in energy metabolism, 
adiposity, and obesity. The potential in vivo, beneficial effects of these polyphenols on 
adiposity and obesity as complementary agents in the up-regulation of energy expenditure 
have emerged by investigating these compounds in cell cultures, animal models of obesity 
and in some human clinical and epidemiological studies. In this brief review, the efficacy 
of the above-named polyphenols and their potential efficacy to modulate obesity and some 
associated disorders are discussed. 









The prevalence of overweight and obesity and associated metabolic complications and related 
morbidity has increased dramatically in the past two decades [1].  Obesity or body mass index   
(BMI) > 30 kg/m
2 is a disease that affects more than 30% of United States adults, with a higher 
incidence among women. It is expected that one in three children born in the early current century will 
develop diabetes associated with obesity [1,2]. In addition to diabetes, obesity is a major risk factor for 
cardiovascular diseases, several forms of cancer (such as breast, colon, and prostate), pulmonary, 
osteoarticular and metabolic diseases [3-8].  It also accounts for 5–7% of the national health 
expenditure in the United States [9]. Thus, obesity is considered a major threat to the public’s health. 
Diet and behavioral modification programs for weight loss and the prevention of weight regain aim to 
reduce energy intake and to increase energy expenditure. However, the ineffectiveness of most 
approaches is seen in the fact that the prevalence of obesity is at an all-time high and that weight 
regain is common [10]. Over the past two decades, chemicals derived from plants and known as 
“phytochemicals” have gained the interest of public and scientific communities for their role in 
maintaining health and preventing disease. Polyphenols derived from many components of the human 
diet are among the leading phytochemicals, and some of their potential preventive and therapeutic 
properties have been studied extensively. In this review, the polyphenols with potential efficacy to 
modulate obesity and associated disorders are briefly discussed. 
2. Catechins  
Second only to water, tea is one of the most popular beverages and is widely consumed throughout 
the world. Several forms of tea including green, black, oolong and white teas are prepared from the 
harvest of leaves from the Camellia sinensis plant. The teas differ by their processing and bioactive 
chemical contents.  Green tea has been well-investigated and is recognized by ancient Chinese 
medicine as having many significant health effects on humans. In recent years, the health benefit 
effects of green tea are mainly attributed to high concentrations of polyphenols, which are collectively 
called catechins. Green tea contains five major catechins including: catechin, epicatechin, epicatechin 
gallate, epigallocatechin, and epigallocatechin gallate (EGCG); the latter comprises more than 40% of 
the total polyphenolic mixture of green tea catechins. Epidemiological, experimental, and clinical 
studies have suggested several beneficial effects from consuming green tea: antioxidant and   
anti-inflammatory activities, cancer and cardiovascular disease prevention properties, and anti-obesity.  
The anti-obesity effect of green tea is mainly attributed to catechins, in particular EGCG, which 
exhibits its anti-obesity effects through several mechanisms including suppression of adipocyte 
differentiation and proliferation, inhibition of fat absorption from the gut, and suppression of catechol-
o-methyl transferase (COMT), an enzyme that inhibits fatty acid oxidation in brown adipose tissue. 
The mechanism of action of green tea on fat oxidation is reviewed in [11]. EGCG has been shown to 
inhibit 3T3-L1 adipocyte proliferation by decreasing levels of phosphorylated ERK1/2, cdk2 and 
cyclin D1 proteins and cell growth arrest at Go/G1[12]  and by inducing apoptosis in mature   
adipocytes [13].  Nutrients 2010, 2                         
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In adipocytes, lipid storage and energy metabolism is tightly controlled. Adenosin monophosphate 
(AMP) activated protein kinase (AMPK) is the master switch in the regulation of energy metabolism. 
It is activated in response to an increase in the AMP:ATP (adenosine triphosphate) ratio within the 
cell, and therefore acts as a sensor for cellular energy regulation. AMPK is a heterodimer protein, 
which is formed from three subunits: α, β and γ [14]. The binding of AMP with AMPK allosterically 
phosphorylates and activates AMPK [15], which in turn shuts down anabolic pathways and supports 
catabolic pathways through regulating the activity of several key enzymes of energy metabolism. 
AMPK inhibits the accumulation of fat by modulating downstream–signaling components. For 
example, it phosphorylates acetyle CoA carboxylase (ACC) and inhibits activity of this enzyme, down 
regulates fatty acid synthesis pathways, and prevents fat accumulation. Of particular importance, 
AMPK, by direct inhibition of HMG-CoA reductase, regulates the cholesterol synthesis pathway in the 
liver [16]. EGCG has been shown to increase both the expression and phosphorylation of AMPK in 
3T3-L1 cells and the phosphorylation of downstream target, ACC, which leads to suppression of 
esterification of fatty acids to triglyceride and which increases fatty acid oxidation [17]. Therefore, 
through several mechanisms, EGCG and other catechins of tea contribute to the reduction of 
adipogenesis and prevent the growth and expansion of adipose tissue.  
A lower weight gain and a lower adipogenesis observed in mice fed a high-fat diet supplemented 
with EGCG was suggested to be due in part to EGCG’s inhibitory effect on pancreatic lipase activity 
resulting in reduced fat absorption from the gut as indicted by the presence of a high fecal fat   
content  [18,19].  In addition to decreasing fat absorption, several studies have shown that 
supplementing the diet of mice with EGCG decreases diet-induced adipogenesis and obesity by 
enhancing fat oxidation [20]. In brown adipose tissue, lipid–metabolizing enzymes are up-regulated by 
catechins through suppression of COMT, which leads to an increase in norepinephrine with prolonged 
sympathetic stimulation of thermogenesis along with an increase in adenyl cyclase, lipolysis, and fat 
oxidation. Therefore, consumption of green tea, which also contains caffeine with its own 
thermogenesis activity (reviewed in [11]), is regarded to be an effective way to reduce and maintain 
body weight through increasing fat oxidation and energy expenditure. Administration of green tea 
extract or catechins not only has been shown to be effective on reduction of weight gain but also has 
resulted in weight loss as observed in overweight and genetically obese laboratory animals [21].  
There are several epidemiological and clinical studies showing that consuming tea or green tea 
extracts reduces body weight and several indices of metabolic syndrome in humans. A cross-sectional 
human study conducted in Taiwan revealed that habitual drinking of oolong and green tea was 
associated with low body fat, and a longitudinal study from the Netherlands has shown a lower BMI 
with the consumption of catechins [22,23]. Although study results on the effect of tea consumption on 
adiposity and body weight are not consistent, clinical trials have overall shown a beneficial effect from 
consuming high doses of catechins in tea drinks, which effectively resulted in the reduction of body fat 
and body weight, particularly when combined with an exercise regimen [24-29]. While the EGCG 
modulation of fat oxidation is regarded to be an important mechanism by which catechins influence 
adipogenesis, it is important to note that the high intake of catechins or green tea extract containing 
very high doses of EGCG causes hepathotoxicity,  inflammation of and necrotic damage to the   
liver [30,31] The genetic variations between Asian and Caucasian populations might be responsible for 
differential effects of tea consumption on suppression of COMT activity and lipid metabolism. Tea Nutrients 2010, 2                         
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catechins, in addition to decreasing the risk of Type 2 diabetes by reducing body weight gain, may 
have a direct beneficial effect on diabetic patients. It has been shown that consumption of green and 
oolong tea by Type 2 diabetic patients increased glucose uptake by the skeletal muscles through   
up-regulating glucose transporter 4 (Glut 4) and by decreasing translocation of Glut 4 and insulin 
levels in adipose tissue [32,33].  
White tea is another product of the Camellia plant. It is prepared by harvesting buds of tea leaves 
and by a minimal processing, which preserves high amounts of tea polyphenols such as EGCG and 
methyl xanthenes (like caffeine). Sohle et al.  [34]  examined the effect of white tea extract on 
adipogenesis in human subcutaneous pre-adipocytes in culture. They found that incubation of   
pre-adipocytes with white tea extract containing polyphenols and methylxanthines dose-dependently 
decreased triglyceride incorporation into adipocytes during adipogenesis. They also reported that white 
tea extract increased lipolysis-activity in differentiated adipocytes, but the levels of lipolysis was not 
sufficient enough to explain the decrease in triglyceride incorporation into adipocytes. To elucidate a 
potential molecular mechanism in this process, Sohle et al. examined the effect of white tea extract on 
a pattern of expression of adipocyte determination and differentiation factor 1(ADD1)/ sterol 
regulatory element binding proteins (SREBP) -1c, a transcription factor for adipocyte differentiation, 
which also promotes proxisome proliferator-activated receptor (PPAR)γ expression [35]. PPARγ is the 
master regulator of adipogenesis [36,37]. Using immunofluorescence microscopy, they observed that 
extract of white tea suppressed ADD1/SREBP-1c signals, which was associated with decreased levels 
of PPARγ as well as CCAAT/enhancer binding protein (C/EBP)α and C/EBPδ mRNA levels during 
adipogenesis, suggesting that it may exert its effect through increasing lipolysis and by inhibiting 
adipogenesis. They noted that when they used human visceral pre-adipocytes, neither white tea extract 
nor EGCG could reduce triglyceride accumulation. They also reported that the effect of white tea 
extract in the reduction of adipogenesis is not through modulation of SIRT  1  (silent information 
regulation 2 homolog 1) levels which is known to modulate cellular metabolism. SIRT 1 is one of the 
7 enzymes in the sirtuins family of enzymes [38], and it is known to regulate adipogenesis through 
inhibiting genes that are involved in adipocyte differentiation and triglyceride accumulation [39].  
3. Anthocyanins and Blueberries  
Blueberries are fruits from the Vaccinium plant. The fruits are rich in phenolic compounds such as 
hydroxycinnamic acids, flavonoids, and proanthocyanidines  [40,41]  and more than 20   
anthocyanins  [42]. Several experimental animal studies have suggested that the consumption of 
blueberries, or its bioactive polyphenolic contents with potent antioxidant activities, may provide 
several health benefits including improvement in cognitive function [43] , antioxidant effects [44], 
protection against inflammation [45],  and modulation of obesity and adiposity. Interestingly, 
supplementing a high fat diet of C57BL/6J mice (60% calories from fat) with 2.9 mg/g purified 
anthocyanins extracted from blueberries decreased their body and adipose tissue weight compared to 
high fat-fed controls, whereas supplementing the high fat diet (45% calories from fat) of mice with 
10% freeze-dried extracts of whole blueberries resulted in the increase of body weight gain rather than 
decreasing it [46]. Moreover, the administration of purified anthocyanins from blueberries also 
lowered serum triglycerides, cholesterol and leptin levels. Liver lipids and triglycerides levels, Nutrients 2010, 2                         
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however, were not altered [47]. Food intake in these studies was monitored, and the authors reported 
no significant effect of either blueberry extract or anthocyanins from blueberry on food intake. In a 
most recent study [48], 10% freeze-dried blueberry powder or 1.16 mg/mL purified anthocyanins from 
blueberry did not significantly reduce body weight gain  compared to high fat-fed control mice, 
however mice fed purified anthocyanins from blueberries had a lower percent of body fat. Notably, 
administration of anthocyanine to the high fat-fed mice also altered several obesity-associated 
parameters including fasting blood glucose and leptin levels and enhanced β-cell function. Blueberry 
juice supplementation, however, did not change these parameters except for lowering leptin levels. 
Leptin is a hormone produced by adipocytes [49,50], which reduce triglycerides formation in various 
organs by increasing free fatty acid (FFA) oxidation and decreasing its esterification to triglyceride; 
thus,  it  reduces  insulin  resistance  and  β-cell dysfunction, which is known to lead to obesity and 
associated diabetes [51]. At present, it is not known why and how anthocyanins from blueberries, but 
not blueberry extract or juice, reduce adiposity and associated parameters. It was suggested that the 
absorption and bioavailability of anthocyanins from the gut might be hindered by the presence of 
sugars, carbohydrates, and lipids in the whole blueberry extract [48]. 
Biotransformation of blueberry juice by bacteria (Serratia vacinii) has been shown to increase the 
phenolic content of blueberry juice and to quadruple its antioxidant activity. When administered to 
KKA
y mice (40 mL·kg
-1/day, for three weeks), a model of obesity and diabetes, the biotransformed 
juice reduced body weight gain, abdominal fat pads, and liver weights possibly through its anorexic 
effect. However, when biotransformed juice was chronically administered (80 mL·kg
-1/day), no 
reduction in body weight gain was observed, but it reduced blood glucose levels, tended to reduce 
blood insulin levels, and increased adiponectin levels  in diabetic mice [41]. Adiponectin is an 
adipocytokine and has been shown to reverse insulin resistance in obese mice. Adiponectin also lowers 
muscle triglyceride levels by increasing influx and combustion of free fatty acids resulting in a 
decreased hepatic level of triglycerides [52]. 
In another study, supplementing a high fat diet (60% calories from fat) of C57BL/6J mice with a 
4% freeze-dried, whole blueberry powder showed no attenuation of weight gain or adipose tissue 
weight. However, freeze-dried whole blueberry increased insulin sensitivity and improved glucose 
homeostasis in mice [53]. Adipocyte death in adipose tissues is one of the phenomena that occur with 
diet induced obesity. The dead adipocytes attract macrophages to the adipose tissue resulting in release 
of proinflammatory cytokines  like  TNF-α,  IL-6 and MCP-1. The chronic production of these 
inflammatory cytokines can  lead to the development of insulin resistance  [31,42,46,54]. Mice 
supplemented with 4% blueberry extract showed a protection against adipocyte death along with a 
down-regulation in macrophage gene expression of TNF-α and IL-10. The gene expression of CD11c 
as a surface marker for macrophages was also down regulated indicating an inhibition of macrophage 
infiltration  [53]. Although the effects of blueberry extracts in different studies do not indicate a 
beneficial effect on obesity, it was found that the parameters affected by obesity such as insulin 
sensitivity and inflammation are attenuated by blueberry supplementation. 
 
 




Resveratrol is a well-studied polyphenol, present in red grapes, red wine, peanuts, and ground nuts. 
It has antioxidant and anti-inflammatory properties [55] and has been suggested to be effective in 
preventing the development of several diseases including cardiovascular disease, diabetes, cancer, and 
obesity [56-58]. Resveratrol’s beneficial effects on obesity are reported to be due in part to its ability to 
increase the phosphorylation and activation of AMPK, the master regulator of energy metabolism, 
which  up-regulates fatty acid oxidation and  increases  uptake of glucose through Glut 4  
translocation  [59].  Resveratrol has also been suggested to increase glucose uptake through   
up-regulation of estrogen receptor-α, which in turn increases Glut 4 expression through phosphatidyle 
inositol-3 kinase (PI3K) and AKT pathway. Furthermore, through up-regulation of SIRT 1, resveratrol 
increases PPARγ  coactivator (PGC)-1α  leading  to  mitochondrial  biogenesis,  oxidative 
phosphorylation, and thus contributes to the suppression of lipid accumulation [60,61]. Ahn et al. [60] 
found that resveratrol supplementation also increased the liver’s expression of SIRT 1 and suppressed 
expression of PPARγ, accumulation of fat in liver of mice fed high fat atherogenic diet.   
Floyd  et al.  [61]  have shown that treatment of 3T3-L1 cells with resveratrol reduced PPARγ 
expression in part through ubiquitin-dependent proteasome degradation. The addition of resveratrol to 
rat isolated hepathocytes has also been shown to inhibit fatty acid and triglyceride synthesis; thus, it 
contributes to resveratrol’s lipid lowering effect [62]. Cell culture studies also revealed that resveratrol 
enhances lypolitic activity in adipocytes through induction of cAMP [63] and inhibits adipogenesis in 
isolated human adipocytes. These effects of resveratrol have been shown to be potentiated when 
combined with genistein [64,65]. Thus, resveratrol, through these metabolic effects, may exert several 
beneficial effects in the prevention of obesity and diabetes. Indeed, several laboratory animal studies 
have shown that resveratrol treatments significantly reduced fat depots size and total body fat in high 
fat fed and genetically obese rodents. The treatment of rats consuming a hypercaloric diet with 30 mg 
resveratrol per kg b.w. for 6 weeks reduced total adipose tissue [66] and reduced visceral fat and liver 
mass indices in rates fed a high fat diet [67]. In obese Zucker rats, the administration of resveratrol was 
not as effective as with regular rats fed a high fat diet, but it reduced plasma triglycerides, free fatty 
acids, cholesterol, and liver triglycerides [68]. Giving resveratrol to mice fed a high fat diet diminished 
total body fat content and decreased epididymal, inguinal, and peritoneal adipose tissues [60,69]. Mice 
fed a high fat-atherogenic diet supplemented with 125 mg resveratrol/kg diet gained less body weight 
and accumulated less total fat and triglyceride; further, they had a lower liver weight compared to  
non-supplemented mice [60]. The microarray analysis of genes in the liver revealed that resveratrol 
supplementation down-regulates the expression of genes involved in lipogenesis. In animal models of 
diabetes, resveratrol reduced blood insulin levels and hyperglycemia (reviewed in [70]). Through its 
antioxidant activity, resveratrol may also prevent oxidative damages resulting from impaired glucose 
metabolism, and thus may prevent the pathogenesis of diabetic complications. Several lines of 
evidence also indicate that administering resveratrol to rodent models induces the kind of biological 
changes comparable to those observed in caloric restriction, such as an increase in longevity and motor 
functions, as well as prevention of cardiac and skeletal muscle dysfunction associated with aging [71]. 
Resveratrol,  through its antioxidant and anti-inflammatory properties,  has been shown to protect 
against liver damage induced by hepathotoxins (reviewed in [72]). No adverse effects of resveratrol Nutrients 2010, 2                         
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have been reported in rabbits and rats, and only mild effects in a few cases were reported in human 
studies [54]. However, very high doses of resveratrol (3,000 mg/kg b.w./day) (<<<repeats later in 
sentence) in one study resulted in anemia and nephrotoxicity within 4 weeks in female rats showing a 
high sensitivity to resveratrol toxicity[73]. This level of high dose resveratrol also showed toxicity to 
the  liver as determined by high levels of alanine transaminase, alkaline phosphatase,  and total   
bilirubin [73,74]. In another study, old mice treated with 14.09 mg resveratrol/L in drinking water had 
increased oxidative damage in the kidneys as measured by 8-hydroxy-2’-deoxyguanosine [75]. Several 
human clinical studies have examined the bioavailability of resveratrol using doses between 25 mg per 
person to 5 g per person. A Phase I, dose-escalation pharmacokinetic study using 0.5–5 g per healthy 
volunteer did not exhibit adverse effects in humans.  
While compelling evidence from molecular, cell culture, and animal studies suggest that resveratrol 
potentially contributes to the prevention of obesity through multiple mechanisms, epidemiological or 
clinical studies  are needed to support  whether the consumption of resveratrol  is  also effective in 
preventing obesity in humans.  
5. Curcumin 
Curcumin is the major, bioactive polyphenol present in the spice turmeric, which is the ground 
rhizome of the perennial herb Curcuma longa. In addition to being used as a spice and colorant, 
turmeric has been used in Asian medicine since the second millennium BC [76]. Curcumin is a low 
molecular polyphenol with several biological properties. It has been shown to possess antioxidant, 
anti-inflammatory, anticancer, anti-angiogenesis, chemopreventive and chemotherapeutic   
properties [77]. The first report referring to curcumin’s effect on disease in humans was published in 
The Lancet about 80 years ago [78]. Rao et al. reported that curcumin supplementation at the dose of 
500–1,000 mg/kg in rat diet reduced liver cholesterol and increased bile acid excretion [79]. At a dose 
of 250 mg/kg, curcumin was also reported to reduce weight gain in rats after 4 weeks and tended to 
reduce liver weight as well as blood triglyceride and free fatty acids levels [80]. 
In addition to the above-mentioned earlier studies, recent cell culture and animal studies have 
explored the impact of curcumin on lipid metabolism, adiposity, and inflammation in more detail. 
Curcumin may have a significant effect on adiposity and lipid metabolism through several mechanisms 
including modulation of energy metabolism, inflammation, and suppression of angiogenesis. It has 
been well established that angiogenesis plays pivotal roles in the growth and expansion of adipose 
tissue (reviewed in [81-84]) Since curcumin is known to suppress angiogenesis, it has mainly been 
investigated for its effect on cancerous tumor growth. However, it may play an important role in the 
growth and expansion of adipose tissue as well. It is known that through down-regulation of several 
factors including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) 
and epidermal growth factor (EGF), as well as angiopoietin and hypoxia-inducible factors (HIF)-1α, 
curcumin suppresses angiogenesis and restricts the growth of tumors [85,86]. Therefore, curcumin 
may contribute to the prevention of adipogenesis through suppression of angiogenesis into the adipose 
tissue  [87]. In adipose tissue, angiogenesis is mediated by adipose tissue secretion of adipokines 
including leptin, adiponectin, resistin, visfatin, tumor necrosis factor (TNF)-α, interleukin(IL)-6, IL-1, 
and VEGF [88]. Therefore, the inhibition of angiogenesis in adipose tissue can be used as a strategy to Nutrients 2010, 2                         
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prevent the growth of adipose tissue and thus, obesity. We have demonstrated this effect of curcumin 
in our recent study [89] where supplementing a high fat diet of C57BL/6J mice with curcumin reduced 
microvessel density as an indication of suppression of angiogenesis in adipose tissue.  
Like other polyphenols reviewed above, we in our recent study found that curcumin activated 
AMPK and down-regulated ACC activity through phosphorylation of this enzyme, which in turn 
down-regulated the flow of acetyl CoA to malonyl CoA leading to up-regulation of carnitine 
palmitoyltransferase-1 (CPT-1), which transfers cytosolic long-chain fatty acyl CoA into the 
mitochondria for oxidation [90]. In addition, through activation of AMPK, curcumin down-regulated 
synthesis of glycerol lipids by inhibiting glycerol-3-phosphate acyl transferase-1 (GPAT-1) activity, 
which esterifies fatty acids to glycerol to form triglycerides for storage [89].  
These effects of curcumin on energy metabolism were observed both in adipocyte cultures and in 
adipose tissue of mice fed a high fat diet. Several other studies in animal models of obesity have 
reported the beneficial effects of curcumin on body weight and fat, adiposity, and energy metabolism. 
Asai and Miyazawa [91] reported that relatively high dietary curcumin supplementation (2 and 10 g/kg 
diet) for two weeks in rats reduced epididymal adipose tissue, attenuated liver fatty acid synthesis, and 
increased rat liver acetyl CoA oxidase activity, which is the first catalytic enzyme in fatty   
acid β-oxidation. Recently, it was reported that supplementing the high fat diet of hamsters with   
500 mg/kg curcumin reduced the levels of free fatty acid, total cholesterol, triglycerides, and leptin as 
well as the insulin resistance index [92]. The hypoglycemic effect of ethanolic extract of turmeric has 
also been reported in genetically diabetic KK-Ay/Ta mice [93]. Jang et al.  also reported that in 
hamsters fed a high fat diet, curcumin supplementation increased the hepatic β-oxidation and 
decreased fatty acid and cholesterol synthesis [92]. These observations are in support of our findings 
that curcumin supplementation suppressed a high fat diet-induced fatty liver in mice and reduced 
plasma levels of cholesterol, triglycerides, glucose, and free fatty acids. In a mouse model of insulin 
resistant obesity, Weisberg et al.  [94]  recently reported that inclusion of a generous amount of 
curcumin in the diet significantly ameliorated type 2 diabetes and inflammation in the liver as detected 
by a lower expression of nuclear factor (NF)-κB and reduced the infiltration of macrophages in 
adipose tissues. They also reported that although mice consumed more curcumin-supplemented food 
(i.e.,  more calories), they nevertheless displayed a lower body weight and a lower body fat as 
measured by nuclear magnetic resonance (NMR).  
In our study, [89] we also found that curcumin supplementation suppressed expression of PPARγ 
and C/EBPα, transcription factors that are mainly found in adipose tissue and are the key transcription 
factors in adipogenesis and lipogenesis [95]. Curcumin also suppressed differentiation of   
pre-adipocytes to adipocytes, which in turn attenuated adipose tissue growth and expansion. This 
effect of curcumin might have been mediated through suppressing the expression of PPARγ 
transcription factor because a PPARγ agonist, such as thiazolidinedione, induces differentiation of 
human pre-adipocytes and increases subcutaneous adiposity [96].  Therefore, suppression of these 
transcription factors by curcumin is another potential mechanism by which curcumin contributes to the 
suppression of adipogenesis.  
It is worth mentioning that studies on the effect of curcumin on metabolic syndrome and obesity 
have been conducted in the experimental animals, whereas supplementation studies on humans are 
mainly limited to investigations related to curcumin’s anti-inflammatory and anti-cancer properties. Nutrients 2010, 2                         
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Therefore, curcumin’s anti-obesity effect in humans remains to be demonstrated after establishing its 
safety after long-term use. 
6. Concluding Remarks 
Cell culture,  animal,  and  limited  human studies suggest that consumption of foods containing 
certain polyphenols or their corresponding supplements changes lipid and energy metabolism and may 
facilitate weight loss and prevent weight gain. Evidence from pre-clinical and some clinical studies 
indicates that consumption of green and white teas containing catechins, fruits such as blueberries with 
anthocyanins, foods such as red grapes and wine with resveratrol, and spice like turmeric containing 
curcumin may provide several health benefits including improving blood glucose and lipid profiles, 
ameliorating insulin resistance, adiposity and obesity. Current knowledge suggests that the potential 
complementary effect of these polyphenols may occur through several mechanisms: suppression of fat 
absorption from the gut, uptake of glucose by skeletal muscles, suppression of anabolic pathways, 
stimulation of catabolic pathways in adipose tissues, liver and other tissues, inhibition of angiogenesis 
in adipose tissues, inhibition of differentiation of pre-adipocytes to adipocytes, stimulation of apoptosis 
of mature adipocytes, and reduction of chronic inflammation associated with adiposity. It is important 
to note that high doses of these polyphenols in supplement form may have adverse effects. At present, 
there is not sufficient data to support recommending long-term, safe usage of these polyphenols for 
prevention and treatment of obesity. Nevertheless, including foods containing these polyphenols in the 
diet following the US dietary guideline for healthy eating and exercise may help to prevent obesity and 
to maintain an ideal body weight. 
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